SAN FRANCISCO, Aug. 1, 2019 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based
genetic medicines company focused on developing and commercializing
innovative products for serious rare neuromuscular diseases, today
announced that it will participate in the following investor
conferences in August:
SVB Leerink Spotlight Series on Rare & Genetic
Diseases
Natalie Holles,
President and Chief Operating Officer
Format: Fireside Chat
Thursday, August 8, 2019, at
10:00 am ET
Boston, Massachusetts
2019 Wedbush PacGrow Healthcare
Conference
Matthew R.
Patterson, Chairman and Chief Executive Officer
Format: Corporate Presentation
Wednesday, August 14, 2019, at
10:20 am ET
New York, New York
To access the live webcast of the Wedbush presentation, please
visit the Events & Presentations page within the Investors +
Media section of the Audentes website. Following the Wedbush
conference, a replay of the live webcast will be available on the
Audentes website for approximately 30 days. There is no
webcast available for the fireside chat at the SVB Leerink
Spotlight Series on Rare & Genetic Diseases Conference.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a leading AAV-based genetic
medicines company focused on developing and commercializing
innovative products for serious rare neuromuscular diseases.
We are leveraging our AAV gene therapy technology platform and
proprietary manufacturing expertise to develop programs across
three modalities: gene replacement, vectorized exon skipping, and
vectorized RNA knockdown. Our product candidates are showing
promising therapeutic profiles in clinical and preclinical studies
across a range of neuromuscular diseases. Audentes is a
focused, experienced and passionate team driven by the goal of
improving the lives of patients.
For more information regarding Audentes, please visit
www.audentestx.com.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contact:
Sarah Spencer
415.957.2020
sspencer@audentestx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-participate-in-upcoming-investor-conferences-300892713.html
SOURCE Audentes Therapeutics, Inc.